Εμφάνιση απλής εγγραφής

dc.creatorTsivgoulis G., Lioutas V.-A., Varelas P., Katsanos A.H., Goyal N., Mikulik R., Barlinn K., Krogias C., Sharma V.K., Vadikolias K., Dardiotis E., Karapanayiotides T., Pappa A., Zompola C., Triantafyllou S., Kargiotis O., Ioakeimidis M., Giannopoulos S., Kerro A., Tsantes A., Mehta C., Jones M., Schroeder C., Norton C., Bonakis A., Chang J., Alexandrov A.W., Mitsias P., Alexandrov A.V.en
dc.date.accessioned2023-01-31T10:16:48Z
dc.date.available2023-01-31T10:16:48Z
dc.date.issued2017
dc.identifier10.1212/WNL.0000000000004362
dc.identifier.issn00283878
dc.identifier.urihttp://hdl.handle.net/11615/80068
dc.description.abstractObjective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF). Methods: We evaluated consecutive patients with NVAF with nontraumatic, anticoagulantrelated ICH admitted at 13 tertiary stroke care centers over a 12-month period. We also performed a systematic review and meta-analysis of eligible observational studies reporting baseline characteristics and outcomes among patients with VKA-or DOAC-related ICH. Results: We prospectively evaluated 161 patients with anticoagulation-related ICH (mean age 75.66 9.8 years, 57.8% men, median admission NIH Stroke Scale [NIHSSadm] score 13 points, interquartile range 6-21). DOAC-related (n 5 47) and VKA-related (n 5 114) ICH did not differ in demographics, vascular risk factors, HAS-BLED and CHA2DS2-VASc scores, and antiplatelet pretreatment except for a higher prevalence of chronic kidney disease in VKA-related ICH. Patients with DOAC-related ICH had lower median NIHSSadm scores (8 [3-14] vs 15 [7-25] points, p 5 0.003), median baseline hematoma volume (12.8 [4-40] vs 24.3 [11-58.8] cm3, p 5 0.007), and median ICH score (1 [0-2] vs 2 [1-3] points, p5 0.049). Severe ICH (.2 points) was less prevalent in DOAC-related ICH (17.0% vs 36.8%, p 5 0.013). In multivariable analyses, DOAC-related ICH was independently associated with lower baseline hematoma volume (p 5 0.006), lower NIHSSadm scores (p 5 0.022), and lower likelihood of severe ICH (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.13-0.87, p 5 0.025). In meta-analysis of eligible studies, DOAC-related ICH was associated with lower baseline hematoma volumes on admission CT (standardized mean difference 5 20.57, 95% CI 21.02 to 20.12, p 5 0.010) and lower in-hospital mortality rates (OR 5 0.44, 95% CI 0.21-0.91, p 5 0.030). Conclusions: DOAC-related ICH is associatedwith smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH. © 2017 American Academy of Neurology.en
dc.language.isoenen
dc.sourceNeurologyen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85030621358&doi=10.1212%2fWNL.0000000000004362&partnerID=40&md5=3f26894697c787d10a30199d7d822a15
dc.subjectapixabanen
dc.subjectdabigatranen
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitoren
dc.subjectrivaroxabanen
dc.subjectwarfarinen
dc.subjectanticoagulant agenten
dc.subjectvitamin K groupen
dc.subjectadulten
dc.subjectageden
dc.subjectanticoagulant therapyen
dc.subjectArticleen
dc.subjectatrial fibrillationen
dc.subjectbrain blood volumeen
dc.subjectbrain hemorrhageen
dc.subjectcerebrovascular accidenten
dc.subjectCHA2DS2-VASc scoreen
dc.subjectchronic kidney failureen
dc.subjectclinical outcomeen
dc.subjectcontrolled clinical trialen
dc.subjectcontrolled studyen
dc.subjectcross-sectional studyen
dc.subjectdisease severityen
dc.subjectfemaleen
dc.subjecthospital admissionen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmeta analysisen
dc.subjectmulticenter studyen
dc.subjectNational Institutes of Health Stroke Scaleen
dc.subjectneuroimagingen
dc.subjectobservational studyen
dc.subjectpremedicationen
dc.subjectprevalenceen
dc.subjectpriority journalen
dc.subjectprospective studyen
dc.subjectrisk factoren
dc.subjectsystematic reviewen
dc.subjecttertiary care centeren
dc.subjectantagonists and inhibitorsen
dc.subjectatrial fibrillationen
dc.subjectbrainen
dc.subjectCerebral Hemorrhageen
dc.subjectclinical trialen
dc.subjectcomparative studyen
dc.subjectcomplicationen
dc.subjectdiagnostic imagingen
dc.subjectdrug effectsen
dc.subjectoral drug administrationen
dc.subjectStrokeen
dc.subjecttreatment outcomeen
dc.subjectAdministration, Oralen
dc.subjectAgeden
dc.subjectAnticoagulantsen
dc.subjectAtrial Fibrillationen
dc.subjectBrainen
dc.subjectCerebral Hemorrhageen
dc.subjectCross-Sectional Studiesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectObservational Studies as Topicen
dc.subjectProspective Studiesen
dc.subjectStrokeen
dc.subjectTreatment Outcomeen
dc.subjectVitamin Ken
dc.subjectLippincott Williams and Wilkinsen
dc.titleDirect oral anticoagulant-vs Vitamin K antagonist-related nontraumatic intracerebral hemorrhageen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής